[ad_1]
![](https://hitconsultant.net/wp-content/uploads/2024/01/JPM-BioNeMo-Blog.png)
What You Ought to Know:
– Amgen, a worldwide chief in biotechnology, is embarking on a groundbreaking enterprise: Mission Freyja.
– The brand new initiative will harness the facility of an NVIDIA DGX SuperPOD, christened after the Norse goddess of prediction, to speed up drug discovery and improvement by way of AI-powered insights from one of many world’s largest human datasets.
Advance Drug Discovery Utilizing NVIDIA DGX SuperPOD-Powered Perception
- Human Variety Atlas: Freyja will map the panorama of human genetic variation, creating a useful atlas for figuring out drug targets and disease-specific biomarkers. This may pave the way in which for personalised medication, tailoring therapies to particular person sufferers primarily based on their distinctive genetic make-up.
- Precision Drugs Revolution: Outfitted with Freyja’s AI capabilities, Amgen researchers will develop cutting-edge precision medication fashions, probably enabling the creation of individualized therapies for a large number of great ailments.
- Diagnostics Made Simple: By figuring out novel biomarkers, Freyja will empower the event of correct and environment friendly diagnostics for monitoring illness development and response to therapy.
Unleashing the Energy of Information
- DGX SuperPOD: A powerhouse of computing, the SuperPOD boasts 248 NVIDIA H100 Tensor Core GPUs, permitting Amgen to coach state-of-the-art AI fashions in days, not months. This dramatically accelerates the tempo of information evaluation and discovery.
- 200 Petabytes of Insights: Freyja will draw upon deCODE genetics’ huge library of deidentified human knowledge, exceeding 200 petabytes, encompassing almost 3 million people. This unparalleled useful resource supplies a novel window into human range and its position in well being and illness.
“Freyja embodies our dedication to leveraging the convergence of know-how and biotechnology. By combining our world-class human knowledge with NVIDIA’s cutting-edge AI know-how, we’re poised to unlock a brand new period of drug discovery,” mentioned David M. Reese, Amgen’s Chief Expertise Officer.
[ad_2]
Source link